Comparison of Fixed Dose Combination Perindopril/Amlodipin Influence on Target Organ Damage in Patients with Hypertension and Ischemic Heart Disease and without It (Results of EPHES Study)


  • G.D. Radchenko State Institution «National Scientific Center «Institute of Cardiology named after Academician M.D. Strazhesko» of the National Academy of Medical Sciences of Ukraine», Kyiv
  • L.O. Mushtenko State Institution «National Scientific Center «Institute of Cardiology named after Academician M.D. Strazhesko» of the National Academy of Medical Sciences of Ukraine», Kyiv
  • O.O. Torbas State Institution «National Scientific Center «Institute of Cardiology named after Academician M.D. Strazhesko» of the National Academy of Medical Sciences of Ukraine», Kyiv
  • S.M. Kushnir State Institution «National Scientific Center «Institute of Cardiology named after Academician M.D. Strazhesko» of the National Academy of Medical Sciences of Ukraine», Kyiv
  • O.A. Yarynkina State Institution «National Scientific Center «Institute of Cardiology named after Academician M.D. Strazhesko» of the National Academy of Medical Sciences of Ukraine», Kyiv
  • S.V. Potashev P.L. Shupyk National Medical Academy of Postgraduate Education, Kyiv
  • Yu.M. Sirenko State Institution «National Scientific Center «Institute of Cardiology named after Academician M.D. Strazhesko» of the National Academy of Medical Sciences of Ukraine», Kyiv



arterial hypertension, ischemic heart disease, target organs, fixed dose combination


EPHES trial (Evaluation of influence of fixed dose combination Рerindopril/amlodipine on target organ damage in patients with arterial HypErtension with or without iSche­mic heart disease) had aim to compare the effect of fixed-dose combination (FDC) perindopril/amlodipine on blood pressure (BP) decrease and the dynamics of target organ damage patterns in patients with arterial hypertension (AH) with and without ischemic heart disease (IHD). Materials and methods. EPHES study included 60 patients aged over 30 years with AH: the first group — 30 individuals without IHD, the second one — 30 persons with IHD. The follow-up period was 12 months. All patients in the day of randomization were administered FDC perindopril/amlodipine in baseline dose 5/5 mg once a day. If it was necessary (BP > 140/90 mmHg), the doses of FDC components were increased gradually every two weeks to 10/10 mg, and after 6 weeks of treatment, indapamide 1.5 mg was added. 66.7 and 96.7 % of patients from the first and second groups received beta-blockers. All patients underwent the measurement: of body weight and height, office levels of systolic BP (SBP), diastolic BP (DBP) and heart rate (HR), ambulatory BP, pulse wave velocity in elastic (PWVe) and muscle arteries, central SBP, augmentation index adjusted to HR 75 bpm (Aix75), biochemical blood count, echocardiography, echocardiography with Doppler, ankle-brachial index, intima-media thickness. Results. It was found that prescribed therapy based on FDC perindopril/amlodipine, regardless of the presence or absence of IHD, has reduced the office, average daily, daytime, night-time and central BP effectively (to target levels) and safely. At the same time, initially increased day and night BP variability, the value of morning rise of SBP and proportion of patients with circadian non-dipper BP profile have significantly decreased, but these figures were cinsiderably higher in patients with IHD at all stages of treatment. Patients with IHD and without it have no differences in the initial value of АІх75, and against the background of prescribed therapy, there was a significant decrease of this index in both groups, but in patients with IHD this reduction of АІх75 was significantly lower than in the group without IHD that probably was due to more frequent use of beta-blockers. Treatment, effective in terms of reducing BP, has led in both groups to a significant decrease of target organ dama­ge — improving the elastic properties of the aorta and left ventricular diastolic function, reduction in the level of albuminuria, in left ventricular hypertrophy and left atrial size. The degree of PWVe decrease was significantly (P < 0.005) lower in patients without IHD than in the group with IHD — 2.5 ± 0.2 m/s vs 4.4 ± 0.5 m/s. In addition, despite the same degree of reduction in the left ventricular mass, an improvement of left ventricular diastolic function (increased E/A and reduced E/E’) was higher in the group of patients with IHD — by 64.4 and 54.1 % against 39.8 and 23.2 %, respectively (P < 0.05 for both indicators). The maximum value of intima-media thickness has significantly decreased only in patients with IHD. The therapy did not lead to significant changes in biochemical parameters and was well tolerated by patients — adverse events reported in 2 (6.5 %) persons in the group without IHD and in 3 (10 %) patients in the group with IHD (P = NS between groups). The groups did not differ significantly by the dynamics of complaints, and patients with IHD, who had angina at baseline, had a significant decrease in the number of angina attacks per week — from 2.5 ± 0.4 to 1.2 ± 0.2 (P < 0.01). Conclusions. Thus, treatment of AH based on FDC perindopril/amlodipine was effective in reducing BP and regression of target organ damage, regardless of the presence of IHD. Chan­ges of the indicators characterizing the target organ damage were somewhat different in patients with and without IHD that must be considered, when choosing treatment regimen.


Компендіум. Лікарські засоби / Під редакцією акад. В.М. Коваленка та проф. А.П. Вікторова. — К.: Моріон, 2010. — С. Л-219.

Методичні рекомендації Асоціації кардіологів України. Дисліпідемії: діагностика, профілактика та лікування. — К., 2011. — 49 с.

Радченко Г., Муштенко Л.О., Торбас О.О. та ін. Оцінка впливу фіксованої комбінації периндоприл/амлодипін на ураження органів-мішеней у пацієнтів з артеріальною гіпертензією (первинні результати дослідження EPHES) // Артеріальна гіпертензія. — 2015. — № 4. — С. 27-41.

Радченко Г., Муштенко Л.О., Торбас О.О. та ін. Оцінка впливу фіксованої комбінації периндоприл/амлодипін на ураження органів-мішеней у пацієнтів з артеріальною гіпертензією та ішемічною хворобою серця (результати дослідження EPHES) // Артеріальна гіпертензія. — 2016. — № 2. — С. 77-92.

Шевелева О.Е. Поражение органов-мишеней у больных артериальной гипертонией в сочетании с ИБС, проживающих в среднем Приобье: Автореф. дис… канд. мед. наук. — 21 с. — Режим доступу:

2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arte­rial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Journal of Hypertension. — 2013. — Vol. 31. — P. 1281-1357.

Ariff B., Zambanini A., Vamadeva S. et al. Candesartan- and Atenolol-Based Treatments Induce Different Patterns of Carotid Artery and Left Ventricular Remodeling in Hypertension // Stroke. — 2006. — Vol. 37. — P. 2381-2384.

Barron A., Hughes A., Sharp A. et al. Long-Term Antihypertensive Treatment Fails to Improve E/e′ Despite Regression of Left Ventricular Mass An Anglo-Scandinavian Cardiac Outcomes Trial Substudy // Hypertension. — 2014. — Vol. 63. — P. 252-258.

Boutouyrie P., Tropeano A.I., Asmar R. et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study // Hypertension. — 2002. — Vol. 39. — P. 10-15.

Boutouyrie P., Achouba A., Trunet P. et al. for the EXPLOR Trialist Group. Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination The EXPLOR Study // Hypertension. — 2010. — Vol. 55. — P. 1314-1322.

Cay S., Cagirci G., Demir A. et al. Ambulatory blood pressure variability is associated with restenosis after percutaneous coronary intervention in normotensive patients // Atherosclerosis. — 2011. — Vol. 219. — P. 951-957.

Cuffe R.L., Rothwell P.M. Medium-term variability in systolic blood pressure is an independent predictor of stroke // Cerebrovasc. Dis. — 2005. — Vol. 19 (suppl 2). — P. 51.

Daemen J. Diastolic dysfunction and arterial stiffness: the chicken or the egg? // Neth. Heart J. — 2013. — Vol. 21(5). — P. 219-221

Dahlof B., Devereux R., Kjeldsen S. еt al. for the LIFE Study Group. Cardiovascular morbidity and mortality in losartan interventional for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 995-1003.

Flues K., Moraes-Silva I.C., Mostarda C. et al. Car­diac and Pulmonary arterial remodeling after sinoaortic denervation in normotensive rats // Autonomic Neuroscience. — 2012. — Vol. 166. — P. 47-53.

Foppa M., Duncan B., Rohde L. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? // Cardiovasc. Ultrasound. — 2005. — Vol. 3. — P. 17.

Frattola A., Parati G., Cuspidi C., Albini F., Mancia G. Prognostic value of 24-hour blood pressure variability // J. Hypertens. — 1993. — Vol. 11. — P. 1133-1137.

Fukui M., Ushigome E., Tanaka E. et al. Home blood pressure Variability on one occasion is a novel factor associated with Arterial stifness in patients with type 2 diabetes // Hypertension Research — 2013. — Vol. 36. — P. 219-225.

Garca-Garca А., Garca-Ortiz L., Recio-Rodr guez L. et al. Relationship of 24-h blood pressure variability with vascular structure and function in hypertensive patients // Blood Pressure Monitoring. — 2013. — Vol. 18. — P. 101-106.

Iwata S., Jin Z., Schwartz E. et al. Relationship between ambulatory blood pressure and aortic archatherosclerosis // Atherosclerosis. — 2012. — Vol. 221. — P. 427-431.

Kamberi L.S., Bakalli A.B., Budima N.M. et al. Pleiotropic and Lipid-lowering Effects of Statins in Hypertension // Mater Sociomed. — 2012. — Vol. 24 (2). — Р. 84-86.

Kario K., Pickering T., Umeda Y. et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study // Circulation. — 2003. — Vol. 18. — Vol. 107(10). — P. 1401-1416.

Kawai T., Ohishi M., Kamide K. et al. Diferences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function // Hypertension Research. — 2013. — Vol. 36. — P. 232-239.

Klause O., Stumpe К., Agabiti-Rosei Е., Zielinski Т. et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study // Ther. Adv. Cardiovasc. Dis. — 2007. — Vol. 1, № 2. — P. 97-106.

La Rosa J.C., Grundy S.M., Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease // N. Engl. J. Med. — 2005. — Vol. 352(14). — P. 1425-1435.

Levey A., Stevens L., Schmid C. et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate // Ann. Intern. Med. — 2009. — Vol. 150(9). — P. 604-612.

Mancia G., Parati G., Hennig M. et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis(ELSA) // J. Hypertens. — 2001. — Vol. 19. — P. 1981-1989.

Matsui Y., Eguchi K., O’Rourke M. et al. Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients // Hypertension. — 2009. — Vol. 54. — P. 716-723.

McMullan C.J., Bakris G.L., Phillips R.A., Forman J.P. Association of BP variability with mortality among African Americans with CKD // Clinical Journal of the American Society of Nephrology. — 2013. — Vol. 8. — P. 731-738.

Miao C.Y., Su D.E. The importance of blood pressure variability in rat aortic and left ventricular hypertrophy produced by sinoaortic denervation // J. Hypertens. — 2002. — Vol. 20. — P. 1865-1872.

Miao C.Y., Xie H., Zhan L., Su D. Blood Pressure variability is more important than blood pressure Level in determination of end-organ damage in rat // J. Hypertens. — 2006. — Vol. 24 — P. 1125-1135.

Migrino R., Bowers М., Harmann L., Prost R., LaDisa J. Jr. Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness // Journal of Cardiovascular Magnetic Resonance. — 2011. — Vol. 13. — P. 37.

Mottram P.M., Haluska B.A., Leano R. et al. Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease // Heart. — 2005. — Vol. 91(12). — P. 1551-1556.

Munro E., Patel M., Chan P. et al. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis // Eur. J. Clin. Invest. — 1994. — Vol. 24. — P. 766-772.

Nissen S.E., Tuzcu E.M., Schoenhagen P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial // JAMA. — 2004. — Vol. 291(9). — P. 1071-1080.

Olsen M., Wachtell K., Neland K. et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy // Blood Press. — 2005. — Vol. 14. — P. 177-183.

Ozawa M., Tamura K., Okano Y. et al. Identification of an increased short-term blood pressure variability on ambulatory blood pressure monitoring as a coronary risk factor in diabetic Hypertensives // Clinical and Experimental Hypertension. — 2009. — Vol. 31. — P. 259-270.

Palatini P., Penzo M., Racioppaetal. A. Clinical rele­vance of night time blood pressure and of daytime blood pressure variability // Archives of Internal Medicine. — 1992. — Vol. 152. — P. 1855-1860.

Parati G., Lantelme P. Blood pressure variability, target organ damage and cardiovascular event // J. Hypertens. — 2002. — Vol. 20. — P. 1725-1729.

Parati G., Pomidossi G., Albini F., Malaspina D., Mancia G. Relationship of 24-hour blood pressure mean and variability toseverity of target-organ damage in hypertension // J. Hypertens. — 1987. — Vol. 5. — P. 93-98.

Preston Mason R., Walter M.F., Day C.A., Jacob R.F. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic action // Am. J. Cardiol. — 2005. — Vol. 96 (Suppl.). — P. 11F-23F.

Rothwell P., Howard S., Dolan E. et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension // Lancet. — 2010. — Vol. 375. — P. 895-905.

Rothwell P.M., Howard S.C., Dolan E. et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke // Lancet Neurol. — 2010 — Vol. 9(5). — P. 469-480.

Rothwell Р. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension // Lancet. — 2010. — Vol. 375. — P. 938-48.

Sakakura K., Ishikawa J., Okuno M. et al. Exaggera­ted ambulatory blood pressure variability is associated with cognitive dysfunction in the very elderly and quality of life in the younger elderly // Ameriсan J. Hypertens. — 2007. — Vol. 20. — P. 720-727.

Sander D., Kukla C., Klingelhöfer J., Winbeck K., Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study // Circulation. — 2000. — Vol. 102. — Р. 1536-1541.

Schillaci G., Bilo G., Pucci G. et al. Relationship between short-term blood pressure variability and large-artery stifness in human hypertension: in dings from 2 large databa­ses // Hypertension. — 2012. — Vol. 60. — P. 369-377.

Schutte A., Schutte R., Huisman H. et al. Blood pressure variability is significantly associated with ECG left ventricular mass in normotensive Africans: the SABPA Study // Hypertension Research. — 2011. — Vol. 34. — P. 1127-1134.

Sega R., Corrao G., Bombelli M. et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study // J. Hypertens. — 2002. — Vol. 39. — P. 710-714.

Sever P., Dahlöf B., Poulter N. et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial // Eur. Heart J. — 2006. — Vol. 27. — P. 2982-2988.

Sipahi I., Tuzcu E.M., Schoenhagen P. et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis // J. Am. Coll. Cardiol. — 2006. — Vol. 15, № 48(4). — P. 833-838.

Stein J., Korcarz C., Hurst R. et al. American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography carotid intima-media thickness task force endorsed by the socie­ty of vascular medicine // J. Am. Society Echoc. — 2008. — Vol. 21(2). — P. 93-111.

Su D.F., Miao C.Y. Blood pressure variability and organ damage // Clinical and Experimental Pharmacology and Physiology. — 2001. — Vol. 28. — P. 709-715.

Webb А., Fischer U., Mehta Z., Rothwell P. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis // Lancet. — 2010. — Vol. 375. — P. 906-915.

White W. Blood pressure monitoring in Cardiovascular Medicine and Therapeutics. — N. Jersy: Humana Press, 2001. — P. 308.

Williams B., Lacy P. for the CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators Impact of Heart Rate on Central Aortic Pressures and Hemodynamics Analysis From the CAFE (Conduit Artery Function Evaluation) Study: CAFE-Heart Rate // J. Am. Coll. Car­diol. — 2009. — Vol. 54. — P. 705-713.

Zanchetti А., Gene Bond М., Hennig М. et al. Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial // Circulation. — 2002. — Vol. 106. — P. 2422-2427.

Zhang Y., Agnoletti D., Safar M.E., Blacher J. Effect of Antihypertensive Agents on Blood Pressure Variability The Natrilix SR Versus Candesartan and Amlodipine in the Reduction of Systolic Blood Pressure in Hypertensive Patients (X-CELLENT) Study // Hypertension. — 2011. — Vol. 58. — P. 155-160.



Clinical Researches